Ozoralizumab
Ozoralizumab is a monoclonal antibody designed for the treatment of rheumatoid arthritis. It is developed by Ablynx, a subsidiary of Sanofi. Ozoralizumab is a Nanobody, a type of antibody that is significantly smaller than conventional antibodies. This allows it to penetrate tissues more effectively and bind to its target with high specificity and affinity.
Mechanism of Action[edit]
Ozoralizumab works by binding to tumor necrosis factor alpha (TNFα), a protein that plays a key role in the inflammatory process of rheumatoid arthritis. By blocking the action of TNFα, ozoralizumab can reduce inflammation and slow the progression of the disease.
Clinical Trials[edit]
Ozoralizumab has undergone Phase II clinical trials for the treatment of rheumatoid arthritis. The results showed that the drug was well tolerated and had a significant effect on reducing the signs and symptoms of the disease.
Potential Side Effects[edit]
As with all medications, ozoralizumab may cause side effects. These can include nausea, headache, and fatigue. More serious side effects can include infection due to the suppression of the immune system.
See Also[edit]
References[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
